(Wired) – One biotech startup, rBIO of Houston, is aiming to make insulin more affordable by producing a copycat version of the drug—known as a biosimilar. It’s not the only company developing biosimilar insulin, but it says it has invented a new process to do so using custom-made bacteria. (Read More)